Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Inhibition of Hypertrophy and Improving Chondrocyte Differentiation by Mmp-13 Inhibitor Small Molecule Encapsulated in Alginate-Chondroitin Sulfate-Platelet Lysate Hydrogel Publisher Pubmed



Jahangir S1 ; Eglin D2 ; Potter N2, 3 ; Khozaei Ravari M4 ; Stoddart MJ2, 3 ; Samadikuchaksaraei A1, 5, 6 ; Alini M2 ; Baghaban Eslaminejad M4 ; Safa M1, 5, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Ao Research Institute Davos, Clavadelerstrasse 8, Davos, 7270, Switzerland
  3. 3. Department of Orthopedics and Trauma Surgery, Faculty of Medicine, Medical Center Albert-Ludwigs University, Albert-Ludwigs University of Freiburg, Freiburg im Breisgau, Germany
  4. 4. Department of Stem Cells and Developmental Biology, Cell Science Research Center Royan Institute for Stem Cell Biology and Technology, Acecr, Tehran, Iran
  5. 5. Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Hematology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

Source: Stem Cell Research and Therapy Published:2020


Abstract

Background: Mesenchymal stem cells are a promising cell source for chondrogenic differentiation and have been widely used in several preclinical and clinical studies. However, they are prone to an unwanted differentiation process towards hypertrophy that limits their therapeutic efficacy. Matrix metallopeptidase 13 (MMP-13) is a well-known factor regulated during this undesirable event. MMP-13 is a collagen degrading enzyme, which is also highly expressed in the hypertrophic zone of the growth plate and in OA cartilage. Accordingly, we investigated the effect of MMP-13 inhibition on MSC hypertrophy. Methods: In this study, 5-bromoindole-2-carboxylic acid (BICA) was used as an inhibitory agent for MMP-13 expression. After identifying its optimal concentration, BICA was mixed into a hydrogel and the release rate was studied. To prepare the ideal hydrogel, chondroitin sulfate (CS) and platelet lysate (PL) were mixed with sodium alginate (Alg) at concentrations selected based on synergistic mechanical and rheometric properties. Then, four hydrogels were prepared by combining alginate (1.5%w/v) and/or CS (1%w/v) and/or PL (20%v/v). The chondrogenic potential and progression to hypertrophy of human bone marrow-derived mesenchymal stem cell (hBM-MSC)-loaded hydrogels were investigated under free swelling and mechanical loading conditions, in the presence and absence of BICA. Results: Viability of hBM-MSCs seeded in the four hydrogels was similar. qRT-PCR revealed that BICA could successfully inhibit MMP-13 expression, which led to an inhibition of Coll X and induction of Coll-II, in both free swelling and loading conditions. The GAG deposition was higher in the group combining BICA and mechanical stimulation. Conclusions: It is concluded that BICA inhibition of MMP-13 reduces MSC hypertrophy during chondrogenesis. Graphical abstract: [Figure not available: see fulltext.] © 2020 The Author(s).